Navigation Links
Chinese CDC and Aeras sign agreement to collaborate on TB vaccine R&D
Date:8/2/2013

Beijing, China/Rockville, MD, USAAugust 2, 2013 With the global tuberculosis epidemic becoming more deadly, costly, and difficult to treat, Chinese Center for Disease Control and Prevention (China CDC) and Aeras today signed a memorandum of understanding to advance research and development of new tuberculosis vaccines. An improved TB vaccine offers the best hope for eliminating this airborne infectious disease that kills 1.4 million people worldwide each year.

While China has achieved significant reductions in TB illness and death over the past 30 years, TB remains a major public threat, with over one million new cases in China each year. A study published in the New England Journal of Medicine last year found that one in 10 cases of TB in China are resistant to the most commonly-used drugs. Based on the World Health Organization's estimates of global multidrug-resistant TB (MDR-TB), China has the highest annual number of cases of MDR-TB in the worlda quarter of the cases worldwide.

The new collaboration between China CDC and Aeras will accelerate research efforts for new vaccines by supporting studies that determine the incidence of TB infection, and will aim to strengthen the capacity within China to conduct future vaccine clinical trials.

"Innovation is the key to controlling and ultimately eliminating this disease," said Dr. Wang Yu, China CDC Director General. "And we have embraced innovation in our TB control efforts in China. We have adopted the latest technologies to diagnose TB. We have advanced innovative approaches to address TB and drug-resistant TB, and to promote the research that is necessary to urgently develop needed new tools to prevent, diagnose and treat it. We have made TB a high priority on our public health agenda, and will continue to seek out new and better ways to prevent and treat TB in communities across our country. But we know that this will not be enough. We will not defeat TB in our country or in the world without new, more effective vaccines. There is a coordinated, global effort underway to develop these urgently needed vaccines, and China must be a partner in this endeavor. With that goal in mind, we are excited to announce a new collaboration with Aeras to advance the research and development of new, more effective vaccines."

China CDC is a nonprofit institution working in the fields of disease control and prevention, public health management and provision of services. Aeras is a nonprofit biotech based in Maryland, USA and Cape Town, South Africa, with the mission of advancing tuberculosis vaccines for the world. The meeting also marks the official opening by Aeras of an office in Beijing to facilitate and strengthen collaboration with Chinese researchers, partnerships that will be critical for developing tuberculosis vaccines for China and the world. Aeras supports half of the vaccine candidates currently in clinical trials, along with a portfolio of earlier stage candidates.

TB vaccine research and development requires dedicated investment and broad support to address scientific complexities and costs. No one organization or institution can do it alone, therefore global partnerships between individuals, research organizations, academic institutions, funders, policy-makers, and others are essential to advance TB vaccine science.

"Collaboration with Chinese researchers is crucial if we are going to defeat this global infectious disease killer," said Tom Evans, president & CEO of Aeras. "China has the technical expertise, resources and desire to develop effective vaccines against TB. Because of the high incidence of TB, the technical expertise, and a vaccine development infrastructure, China is perfectly poised to be at the forefront of global prevention efforts."

The global TB epidemic requires novel approaches, new tools and sufficient resources to mitigate what is now a more challenging and expensive disease to control than when the World Health Organization declared it a global emergency more than 20 years ago. The emergence of MDR-TB, now found in all countries surveyed worldwide, is confounding global efforts to halt the spread of TB and is putting an enormous economic burden on health systems globally. Alarmingly, new genetic research suggests that the bacterium could be poised to emerge stronger and more deadly than ever before, making it especially well-suited to spreading disease in a highly mobile and densely populated world.

"The ultimate game-changer in the battle to eliminate TB would be an improved vaccine that prevents children and adults from developing and transmitting disease," added Evans. The MOU was signed today during a meeting of global TB experts from the World Health Organization and other global leaders in TB research.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. UCLA and Chinese scientists analyze genetic makeup of human and mouse embryos in amazing detail
2. 4leafcity.com Has Launched a Promotional Offer on Chinese Traditional Dresses
3. International Food Protection Training Institute Hosts Chinese Delegation
4. Daily QiGong and Chinese Medicine Improves Health Says Alternative Medicine Pioneer
5. Chinese Pharma Giant Launches Mobile Phone Anti-Counterfeiting Crusade in Africa
6. PolyU and University of Chinese Academy of Sciences Launch Joint PhD Supervision Scheme for Management Students
7. Dam it! Chinese Hackers Tangling with US Infrastructure Again?
8. Traditional Chinese Medicine Hospitals in China Industry Research Report – Now Available from IBISWorld
9. Launch of Chinese-German Center for Bio-Inspired Materials at Mainz University Medical Center
10. Indoor air puts Chinese women nonsmokers at risk
11. Residents near Chinese e-waste site face greater cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency ... emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... , ... February 10, 2016 , ... The recreational use ... enthusiasts in the state still face a lot of restrictions as to where they ... intended for private, personal use” and that cannabis “may not be consumed openly or ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 CSI Specialty Group (CSI) expanded its ... the Specialty Pharmacy Podcast. A free, weekly show, the ... real-world education, discussion and context amongst specialty pharmacy peers ... --> The Specialty Pharmacy Podcast, hosted by ... Group Suzette DiMascio, CHE, CMCE, CPC, is available for ...
(Date:2/10/2016)... Switzerland and SAN DIEGO ... , Inc., a global leader in viral gene therapy ... therapy treatments for congestive heart failure and other chronic ... develop a scalable manufacturing process and produce cGMP-grade RT-100 ... trials. --> --> ...
(Date:2/10/2016)... Feb. 10, 2016 Urologix, the market leader ... of Benign Prostatic Hyperplasia (BPH), announces new private ownership ... , a medical device industry veteran of more than ... Liability Company.  Plymouth, Minn. ... Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue to ...
Breaking Medicine Technology: